TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer
Interventions:   Drug: TAS 102;   Drug: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting

https://ift.tt/2N6PKT1